Actively Recruiting
Imaging Pulmonary Aspergillosis Using Gallium-68-Deferoxamine PET/CT
Led by Radboud University Medical Center · Updated on 2025-05-22
10
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of gallium-68-deferoxamine ([68Ga]Ga-DFO-B) PET/CT imaging to detect pulmonary Aspergillus infections, including chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. These fungal infections are increasing and can be difficult to diagnose with standard invasive tests. This phase 2 trial aims to show the feasibility of this non-invasive imaging method to visualize infections and distinguish them from cancer. Participants will receive a single intravenous injection of a fixed dose of 100 MBq ± 10% of [68Ga]Ga-DFO-B, containing 100 micrograms of deferoxamine (DFO-B). A PET/CT scan will be performed 60 minutes after the injection to observe how the radiopharmaceutical accumulates at the infection site. This single-center, open-label trial involves a single study visit. During the visit, participants undergo the PET/CT scan and researchers measure standardized uptake values and target-to-background ratios of the radiopharmaceutical to evaluate infection visualization. Participants must be able to lie still during the scan. The total participation involves just this one visit, and the study monitors how well this imaging technique works for diagnosing pulmonary aspergillosis.
CONDITIONS
Brief Title
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The patient is at least 18 years old on the day of inclusion.
- The patient has suspected chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis.
- There is no significant interference with standard care and follow-up.
You will not qualify if you...
- The patient is pregnant or planning on becoming pregnant.
- The patient has severe kidney dysfunction with eGFR < 30 ml/min/kg and/or receives dialysis.
- The patient has (chronic) iron overload.
- The patient has been receiving antifungal treatment for more than 48 hours prior to the study day.
- The patient is not able to lie still in the scanner.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants receive a single intravenous injection of gallium-68-deferoxamine and undergo a PET/CT scan 60 minutes later to evaluate pulmonary aspergillosis.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
RadboudUMC
Nijmegen, Netherlands
Actively Recruiting
Research Team
L
Laura Michon
R
Roger Brüggemann
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here